Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Oncology

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.09.2106PMID 17404367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Effect of screening and adjuvant therapy on mortality from breast cancer.

  2006cited by this paper
• Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast Cancer

  2006cited by this paper
• Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

  2006cited by this paper
• Comment to Anderson WF, Jatoi I, Devesa SS: Distinct Breast Cancer Incidence and Prognostic Patterns in the NCI’s SEER Program: Suggesting a Possible Link Between Etiology and Outcome. Breast Cancer Res Treat 90:127–137, 2005

  2006cited by this paper
• Caring for older women with breast cancer: can observational research fill the clinical trial gap?

  2006cited by this paper
• Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality.

  2006cited by this paper
• Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943–2002)

  2006cited by this paper
• Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome

  2005cited by this paper
• Update in medical oncology for older patients: focus on breast cancer: management of early breast cancer.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

  2005cited by this paper
• Effect of screening and adjuvant therapy on mortality from breast cancer

  2005cited by this paper
• Cancer screening.

  2005cited by this paper
• Hazard rates of recurrence following diagnosis of primary breast cancer

  2004cited by this paper
• Is Male Breast Cancer Similar or Different than Female Breast Cancer?

  2004cited by this paper
• Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.

  2004cited by this paper
• Undertreatment strongly decreases prognosis of breast cancer in elderly women.

  2003cited by this paper
• Participation of patients 65 years of age or older in cancer clinical trials.

  2003cited by this paper
• Why is breast-cancer mortality declining?

  2003cited by this paper
• Trends in Breast Cancer by Race and Ethnicity

  2003cited by this paper
• Cancer screening

  2002cited by this paper
• Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.

  2002cited by this paper
• Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force

  2002cited by this paper
• Re: Biologic characteristics of interval and screen-detected breast cancers.

  2001cited by this paper
• National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

  2001cited by this paper
• Mammography screening interval and the frequency of interval cancers in a population-based screening.

  1997cited by this paper
• 1995 Oxford Breast Cancer Overview-Preliminary Outcomes.

  1996cited by this paper
• Hazard function estimation using B-splines.

  1995cited by this paper
• A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer.

  1994cited by this paper
• Adjuvant systemic therapy for early breast cancer

  1994cited by this paper
• Breast cancer in aging women. A population‐based study of contrasts in stage, surgery, and survival

  1989cited by this paper
• The jackknife, the bootstrap, and other resampling plans

  1987cited by this paper
• National institutes of health consensus development conference statement: Adjuvant chemotherapy for breast cancer. september 9‐11, 1985

  1986cited by this paper
• Controlled trial of tamoxifen as adjuvant agent in management of Early Breast Cancer:Interim analysis at four years by the Novaldex Adjuvant Trial Originisation.

  1983cited by this paper
• Information Theory and an Extension of the Maximum Likelihood Principle

  1973cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• A community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast cancer survivors (PACHA): protocol for a pilot cluster-randomized controlled trial

  2025cites this paper
• The potential benefits of radiotherapy in elderly patients with early-stage triple-negative breast cancer

  2025cites this paper
• US Breast Cancer Mortality.

  2024cites this paper
• Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells

  2024cites this paper
• Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis

  2024cites this paper
• Obesity, dysbiosis and inflammation: interactions that modulate the efficacy of immunotherapy

  2024cites this paper
• Mechanical Disruption by Focused Ultrasound Re-sensitizes ER+ Breast Cancer Cells to Hormone Therapy.

  2024cites this paper
• Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study

  2023cites this paper
• Personalized Injury Reduction Strategies in Sports Medicine: Lessons Learned from Advances in Breast Cancer Treatment: A Clinical Commentary

  2023cites this paper
• Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer

  2023cites this paper
• Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer.

  2023cites this paper
• Leveraging hypoxia in triple-negative breast cancer as a promising treatment strategy.

  2023cites this paper
• Targeted gene next‐generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer

  2022cites this paper
• Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism

  2022cites this paper
• MOLECULAR SUBTYPES OF BREAST CANCER

  2022cites this paper
• Association between coronary artery disease and clinical outcome in cancer patients: A propensity score matching analysis

  2022cites this paper
• From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data

  2021cites this paper
• Factors associated with late risks of breast cancer-specific mortality in the SEER registry

  2021cites this paper
• Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry

  2021cites this paper
• In Vivo Receptor Visualization and Evaluation of Receptor Occupancy with Positron Emission Tomography.

  2021cites this paper
• Causes of death among women with breast cancer: A follow‐up study of 50 481 women with breast cancer in Finland

  2021cites this paper
• Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.

  2021cites this paper
• Pattern of breast cancer presentation in a tertiary hospital in Lagos, Nigeria

  2020cites this paper
• Association between clinical risk factors and left ventricular function in patients with breast cancer following chemotherapy

  2020cites this paper
• Progestins counteract estrogens to shift breast cancer cell metabolism

  2020cites this paper
• Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer

  2020cites this paper
• Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells

  2020cites this paper
• Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events

  2020cites this paper
• The Effect of Advances in Lung-Cancer Treatment on Population Mortality.

  2020cites this paper
• Radiotherapy after breast‐conserving surgery for elderly patients with early‐stage breast cancer: A national registry‐based study

  2020cites this paper
• Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers

  2020cites this paper
• Diseases of the Breast during Pregnancy and Lactation

  2020cites this paper
• Pregnancy in Breast Cancer Survivors.

  2020cites this paper
• Mammography screening for breast cancer-the UK Age trial.

  2020cites this paper
• Applications of Salivary Bioscience to Precision Medicine

  2020cites this paper
• Cardiovascular Consequences of Skeletal Muscle Impairments in Breast Cancer

  2020cites this paper
• Progestins counteract estrogens to shift breast cancer cells into a quiescent metabolic profile

  2020cites this paper
• The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.

  2020cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Breast Cancer Screening: a Paradigm Change Is Needed—the PB Desai Oration

  2019cites this paper
• Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance

  2019cites this paper
• The history of cancer screening.

  2019cites this paper
• Fluorine-18 Labeled Fluorofuranylnorprogesterone ([18F]FFNP) and Dihydrotestosterone ([18F]FDHT) Prepared by “Fluorination on Sep-Pak” Method

  2019cites this paper
• E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

  2018cites this paper
• Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.

  2018cites this paper
• Sensitivity and Isoform Specificity of 18F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer

  2018cites this paper
• Emerging Innovative Therapeutic Approaches Leveraging Cyclin‐Dependent Kinase Inhibitors to Treat Advanced Breast Cancer

  2018cites this paper
• Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions

  2018cites this paper
• Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012

  2018cites this paper
• Time trends in the prevalence of cancer and non‐cancer diseases among older U.S. adults: Medicare‐based analysis

  2018cites this paper
• Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

  2018cites this paper
• Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.

  2018cites this paper
• Contribution of Breast Cancer to Overall Mortality for US Women

  2018cites this paper
• Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer

  2017cites this paper
• Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

  2017cites this paper
• Real‐world impact of non–breast cancer–specific death on overall survival in resectable breast cancer

  2017cites this paper
• New agents for the management of resistant metastatic breast cancer

  2017cites this paper
• Take care of your neighborhood

  2017cites this paper
• Disease Severity, Presentation, and Clinical Outcomes Among Adolescents With Malignant Breast Neoplasms: A 20‐Year Population‐Based Outcomes Study From the SEER Database (1973‐2009)

  2017cites this paper
• Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

  2017cites this paper
• Imputing estrogen receptor (ER) status in a population‐based cancer registry: a sensitivity analysis

  2017cites this paper
• Potential Use of American College of Radiology BI-RADS Mammography Atlas for Reporting and Assessing Lesions Detected on Dedicated Breast CT Imaging: Preliminary Study.

  2017cites this paper
• Sバンドレーダによって観測された台風によるクラッタの抑圧(電気電子工学科 柳繁教授に捧ぐ)

  2017cites this paper
• The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction

  2017cites this paper
• Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data.

  2017cites this paper
• Triple‐negative breast cancer in the elderly: Prognosis and treatment

  2017cites this paper
• Semiparametric Bayesian analysis of high-dimensional censored outcome data

  2017cites this paper
• Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers

  2017cites this paper
• PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast

  2017cites this paper
• Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

  2017cites this paper
• Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients

  2016cites this paper
• Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study

  2016influential citation
• Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences

  2016cites this paper
• Role of bone scan in addition to CT in patients with breast cancer selected for systemic staging

  2016cites this paper
• Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

  2016cites this paper
• Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer.

  2016cites this paper
• Impact of Comorbidity on Treatment Decision Making and Outcomes

  2016cites this paper
• Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.

  2016cites this paper
• ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization

  2016cites this paper
• Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.

  2016cites this paper
• Comparison of Prognosis according to Tumor Size in Small Breast Cancer with Lymph Node Involvement

  2016cites this paper
• Strategies for the Management of Early-Stage Breast Cancer in Older Women.

  2016cites this paper
• Expression of p53 and Bcl2 Mammary Adenocarcinoma in C3H Mice Administered With Salvia miltiorrhizae Bunge root extract

  2016cites this paper
• The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring

  2016cites this paper
• Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future Directions.

  2016cites this paper
• CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages

  2016cites this paper
• Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.

  2016cites this paper
• Short-term and long-term survival of interval breast cancers taking into account prognostic features

  2016cites this paper
• Dedicated Three-dimensional Breast Computed Tomography: Lesion Characteristic Perception by Radiologists

  2016cites this paper
• Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study

  2015cites this paper
• Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends

  2015cites this paper
• Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer

  2015cites this paper
• Soy isoflavone intake and bone mineral density in breast cancer survivors

  2015cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cites this paper
• Factors influencing treatment adherence and discontinuation in women with breast cancer

  2015cites this paper
• The Effect of Socio-Economic-Cultural Factors on Breast Cancer.

  2015cites this paper
• Whole Breast Ultrasound: Comparison of the Visibility of Suspicious Lesions with Automated Breast Volumetric Scanning Versus Hand-Held Breast Ultrasound.

  2015cites this paper
• PARITY, OBESITY AND BREAST CANCER SURVIVAL: DOES INTRINSIC SUBTYPE MODIFY OUTCOMES?

  2015influential citation
• Bilateral Mastectomy for Unilateral Breast Cancer: a Perplexing Trend

  2015cites this paper